
Valneva SE (VALN) Stock Forecast & Price Target
Valneva SE (VALN) Analyst Ratings
Bulls say
Valneva SE reported a notable 13% year-over-year increase in product sales, reaching €163.3 million in 2024, up from €144.6 million in 2023, indicating robust demand for its vaccine offerings. The company also announced total revenue of €169.6 million for 2024, representing a 10% increase compared to the previous year, bolstered by strong sales expectations for the recently FDA-approved Ixchiq vaccine. With projected sales for Ixchiq anticipated to surpass €100 million within three years of its launch and the global market for chikungunya vaccines expected to exceed $500 million annually, Valneva's growth trajectory suggests positive long-term revenue prospects.
Bears say
Valneva SE is projected to reduce its operating cash burn to below €30 million in 2025, down from over €60 million in 2024, indicating a critical need for cost control amidst declining revenue forecasts. The revenue estimate for 2025 has been lowered to €185 million, a significant decline from the previous estimate of €222.5 million, which reflects a challenging market environment and potential difficulties in sales growth. Furthermore, the earnings per share (EPS) estimate for 2025 has been decreased to (€0.65), suggesting continued financial strain as the company adjusts its revenue expectations and sales forecasts for its Ixchiq vaccine.
This aggregate rating is based on analysts' research of Valneva SE and is not a guaranteed prediction by Public.com or investment advice.
Valneva SE (VALN) Analyst Forecast & Price Prediction
Start investing in Valneva SE (VALN)
Order type
Buy in
Order amount
Est. shares
0 shares